Omnicell, Inc. has faced selling pressures and underperformed the broad indices since late 2021. Q2 FY'23 earnings show decreased sales, particularly in point-of-care revenues, along with a potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results